Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome

Yonsei University1 site in 1 country1,000 target enrollmentSeptember 2013

ConditionsMyelodysplastic Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Myelodysplastic Syndrome
Sponsor: Yonsei University
Enrollment: 1000
Locations: 1
Primary Endpoint: the number of patients with MDS to examine new prognostic factors
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Developing a molecular genetic test that can identify prognostic factors which can predict response to treatment, and to contribute to the establishment of future therapeutic strategies base on prognostic factors by undergoing peripheral blood and bone marrow examination of Myelodysplastic Syndrome (MDS) patients at diagnosis and relapse.

Registry

clinicaltrials.gov

Start Date

September 2013

End Date

September 2023

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Yonsei University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•MDS diagnosed by bone marrow aspiration and biopsy at Severance Hospital.
•Male and Female over 16 years of age. ③ Written consent of the patient to participate in the cohort ④ Deaths during the study period are waiver of consent